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Abstract: Innate immunity plays a critical role in the host response to a viral infection. The 
innate response has two main functions. First, it triggers effector mechanisms that restrict 
the infection. Second, it primes development of the adaptive response, which completes the 
elimination of the pathogen or of infected cells. In vivo, HTLV-1 infects T lymphocytes 
that participate in adaptive immunity but also monocytes and dendritic cells that are major 
players in innate immunity. Herein, we will review the interplay between HTLV-1 and 
innate  immunity.  Particular  emphasis  is  put  on  HTLV-1-induced  alteration  of  type-I 
interferon (IFN-I) function. In vitro, the viral Tax protein plays a significant role in the 
alteration  of  IFN  synthesis  and  signaling.  Despite  this,  IFN-I/AZT  treatment  of  Adult 
T-cell Leukemia/Lymphoma (ATLL) patients leads to complete remission. We will discuss 
a model in which exogenous IFN-I could act both on the microenvironment of the T-cells 
to protect them from infection, and also on infected cells when combined with other drugs 
that lead to Tax down-regulation/degradation. 
Keywords:  HTLV-1;  innate  immunity;  interferon;  monocytes;  dendritic  cells;  natural 
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1. Introduction 
Upon viral infection, several defense mechanisms cooperate to limit propagation of the pathogen 
within  the  organism.  Classically,  two  types  of  immune  responses  have  been  defined:  the  innate 
response, a rapidly engaged but transient and poorly specific response, and the adaptive response, a 
delayed but specific response which allows the development of immune memory.  
1.1. Innate Immune Response 
In  1957,  Isaacs  and  Lindenmann  observed  that  culture  medium  from  influenza-infected  cells 
induced resistance in naive cells. They hypothesized that a substance secreted by the infected cells 
inhibited the viral spread [1]. The term “interferon” was coined to name this interfering substance, 
which was later described as a family of conserved cytokines. Among this family, type I interferons 
(IFN-I,  i.e.,  IFN-  and  IFN-)  are  highly  effective  anti-viral  mediators.  IFN-I  production  is  not 
constitutive but must be induced when the cell senses an infection.  
All cells express viral sensors, either at the cell surface, at the endosomal membrane or in the 
cytoplasm  [2,3].  These  receptors  recognize  structural  motifs  specifically  present  in  pathogens 
and termed  PAMPs  (Pathogen-Associated  Molecular  Patterns).  Examples  of  viral  PAMPs  include 
double-stranded RNA, single-stranded RNA, non-methylated CpG DNA and envelope glycoproteins. 
The  sensors  that  recognize  these  viral  PAMPs,  such  as  TLRs  (Toll-Like  Receptors)  and  RLHs  
(RIG-I-Like Helicases), are referred to as PRRs (Pattern Recognition Receptors). Interaction of the 
PAMPs  with  the  PRRs  triggers  signaling  pathways  that  lead  to  activation  of  IRF3  (Interferon 
Regulatory Factor 3) and IRF7 transcription factors, eventually allowing transcription from the IFN-I 
promoters [4,5]. 
IFN-I displays both autocrine and paracrine effects. Engagement of the IFN-I receptors (IFNAR-1 
and  IFNAR-2)  at  the  cell  surface  induces  activation  of  Jak1/Tyk2  and  STAT1/STAT2  signaling 
cascade that subsequently promotes the expression of a large number of anti-viral effectors known as 
interferon-stimulated genes (ISGs) [6]. As an example, PKR (dsRNA-dependent Protein Kinase), a 
well-studied representative of ISGs, is a serine-threonine kinase that inhibits translation upon viral 
infection by phosphorylating the initiation factor eIF2 [7]. Active PKR limits viral proteins synthesis, 
thus hindering viral replication.  
IFN-I can be produced by all cells upon sensing virus infection, and in particular by innate immune 
cells such as macrophages and dendritic cells (DCs). Plasmacytoid dendritic cells (pDCs) are the major 
IFN-I producers. These CD123
+ CD4
+ CD11c
− DCs are found in an immature stage in the peripheral 
blood, and more predominantly in inflamed tissues [8]. They express TLR7 and TLR9, which trigger 
their maturation upon engagement. Myeloid CD11c
+ CD4
+ dendritic cells (myDCs, also known as 
conventional DCs) represent a distinct TLR1-8 and TLR10-expressing DC type that circulates in the 
blood and constantly migrates into secondary lymphoid organs [8]. Many in vitro studies of DCs use 
myeloid-like DCs generated from CD14
+ monocytes. It should however be kept in mind that such 
in vitro  monocyte-derived  DCs  (MDDCs)  are  not  identical  to  in  vivo  or  ex  vivo-purified  DCs. 
Therefore, those results should sometimes be handled with caution [8]. Viruses 2011, 3                         
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In addition, other effectors of innate immunity such as restriction factors are present in cells before 
infection takes place and can act as immediate inhibitors of a given infectious agent [9]. When these 
proteins are not able to block viral spread, another efficient defense strategy consists of killing the 
infected cells. Members of both the innate system (natural killer cells or NK cells) and the adaptive 
system (cytotoxic T lymphocytes or CTLs) have the ability to kill infected cells. NK cells are able to 
detect abnormal cell surface phenotypes such as the loss of MHC complexes on target cells. Then, they 
induce lysis of this target. Invariant NKT (iNKT) cells are a small population of T cells that express 
cell surface antigens associated with the NK lineage. These cells display attributes of both innate  
and adaptive immunity, and mature iNKT cells modulate the immune response by secreting large 
amounts of cytokines. 
Innate immune cells such as macrophages and DCs belong to the family of professional antigen-
presenting  cells.  They  have  the  capacity  to  capture  antigens,  process  them  and  display  them  to 
lymphocytes [8]. Antigen presentation is therefore a central process in the immune response, since it 
allows priming of the adaptive response, thus bridging the innate and adaptive responses.  For this 
reason,  beyond  the  direct  IFN-I-mediated  anti-viral  role  described  above,  innate  immunity  is  also 
essential for the activation of adaptive immunity. 
1.2. HTLV-1 
It  is  estimated  that  the  human  T-lymphotropic  virus  type  1  (HTLV-1)  retrovirus  infects  15  to  
20 million individuals throughout the world [10]. The HTLV-1 antibody prevalence rate varies from 
0.2 to 10% among adults, depending on the geographical area. It increases with age, in some places 
eventually reaching 20 to 50% of the female population aged 60 and above [11].  
Three  modes  of  transmission  are  known  for  HTLV-1.  (1)  Mother-to-child  transmission,  the 
efficiency of which varies from 10 to 20% and which occurs after prolonged breastfeeding, mainly 
after 6–9 months of age [11,12]. (2) Sexual transmission [13], Japanese studies clearly demonstrated a 
higher transmission efficiency from male to female than from female to male. Such differences might 
account for the increased HTLV-1 seroprevalence with age that is observed in females. (3) Intravenous 
transmission,  mainly  through  blood  transfusion  which  appears  to  be  the  most  efficient  mode  for 
HTLV-1  transmission.  The  risk  of  transmission  after  transfusion  of  infected  blood  products  was 
estimated to reach 15 to 60% [14].  
The two major diseases associated with HTLV-1 (i.e., Adult T-cell Leukemia/Lymphoma or ATLL 
and HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis or HAM/TSP) are described in all 
endemic areas [10]. ATLL is a CD4
+ T-cell malignant lymphoproliferation that is characterized by 
clonal integration of the HTLV-1 provirus in tumor cells [15]. Shimoyama et al. have proposed a 
classification of ATLL into 4 subtypes: smoldering, chronic, lymphoma and leukemic/acute [16]. Both 
chronic and smoldering types can progress into the acute form.  
HAM/TSP is mainly defined as a spastic paraparesis resulting from a chronic immune inflammation 
[17,18]. HAM/TSP is a slowly progressive disorder: after 10 years, roughly 50% of the patients are 
limited to a wheelchair. The possible mechanisms that explain how HTLV-1 causes HAM/TSP include 
(1) a direct toxicity caused by HTLV-1 specific CTLs; (2) autoimmunity; or (3) bystander damage 
caused by cytokines such as TNF-[19]. In most cases, the neurological features include spasticity Viruses 2011, 3                         
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and/or  hyper-reflexia  of  the  lower  extremities,  urinary  bladder  disturbance  and  lower  extremity  
muscle weakness [20].  
Interestingly,  contamination  through  blood  is  associated  with  a  specific  risk  of  developing 
HAM/TSP [21], while early HTLV-1 infection of babies through infected breast-milk appears to be a 
major risk factor for developing ATLL but not HAM/TSP. Indeed, several studies conducted in Japan 
as well as in the Caribbean area and in Brazil have demonstrated that most if not all mothers of ATLL 
patients were infected with HTLV-1 [22,23]. 
The  role  of  innate  immunity  in  HTLV-1  pathogenesis  is  not  clear.  Some  reports  convincingly 
demonstrated that HTLV-1-infected cells do not produce IFN-I and that the Tax protein alters IFN-I 
signaling [24–27]. However, and even if it does not promote cell cycle arrest or cell death in vitro [28], 
the IFN-/AZT combination is particularly efficient for treating leukemic, smoldering and chronic 
ATLL patients and significantly improves their survival [29,30]. In addition, IFN-, when combined 
with arsenic trioxide promotes cell death in vitro through caspase activation, loss of NF-B activation 
and Tax degradation. This regimen was also shown to be efficient in vivo, both in a murine ATLL 
model and for treating ATLL patients [30–37].  
The aim of this review is to provide an overview of the current state of knowledge of the interplay 
between HTLV-1 and innate immunity. Of particular interest will be the following points: (i) Does 
HTLV-1 infect cells that participate in the innate immune response in vivo? (ii) Can the effectors of 
innate immunity (and in particular IFN-I) prevent spread of the virus? (iii) Does HTLV-1 infection 
alter the innate immune response and if so, what are the underlying mechanisms?  
2. HTLV-1 Infects Cells that Play a Major Role in the Innate Immune Response 
In  vivo  and  irrespective  of  the  clinical  status  (i.e.,  in  asymptomatic  carriers  (ACs),  ATLL  or 
HAM/TSP patients) the HTLV-1 provirus is predominantly detected in CD4
+ T lymphocytes [38], 
even if infection of CD8
+ T lymphocytes [39–41], and to a lesser extent of B lymphocytes has also 
been documented [42]. It thus appears that the main in vivo cellular targets of HTLV-1 are cells from 
the adaptive immune system.  
However, innate immune cells (monocytes, macrophages, DCs) are permissive to the virus in vitro 
and/or  are  infected  in  vivo  [39,43–46]  (Table  1).  As  an  example,  in  vivo  infection  of  DCs  was 
demonstrated almost 20 years ago in HTLV-1-infected individuals [45]. However, in the absence of 
any  DC-specific  antibody  available  at  that  time,  characterization  of  the  cell  subtype  remained 
incomplete. More recently, specific infection of myDCs and pDCs was shown in vivo [46]. Although 
myDCs and pDCs represent less than 1% of the cells in the peripheral blood, thus not significantly 
contributing  to  the  total  proviral  load  (PVL),  their  infection  could  greatly  affect  immune  system 
function. Of note, the PVL per 10
4 cells was shown to be proportionally higher in pDCs purified 
from an  HTLV-1  AC  than  in  total  peripheral  blood  mononuclear  cells  (PBMCs)  from  the  same 
individual [46], while this was not the case in HAM/TSP patients [47]. 
How do DCs get infected in vivo? Do they represent a dead-end product or do they play a role in the 
viral transmission? Until recently, the paradigm for HTLV-1 infection was a model in which viral 
transmission required cell-to-cell contact. In 2008, Jones et al. reported that both myDCs and pDCs 
could be productively infected in vitro by cell-free HTLV virions [48]. These DCs could then transmit Viruses 2011, 3                         
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the virus to T lymphocytes. This led to the establishment of a model in which DCs that are present at 
the  site  of  infection  could  be  the  primary  target  cells  in  a  newly  infected  individual,  allowing 
subsequent cell-to-cell transmission of the virus to T cells. Whether these DCs are infected through 
cell-to-cell contact or by cell-free virus in vivo remains to be investigated. However, it is worth noting 
that although present in the plasma [49], most of the HTLV-1 virus remains cell-associated in vivo.  
A critical role was assigned to DC-SIGN (DC-Specific Intercellular adhesion molecule-3-Grabbing 
Non-integrin),  both  for  the  infection  of  DCs  and  for  transmission  of  the  virus  to  T  cells  [50].  
DC-SIGN is a type II transmembrane C-type lectin receptor, whose expression is mostly restricted to 
myDCs [51]. DC-SIGN contains a carbohydrate recognition domain that is involved in binding to the 
HTLV-1 envelope and thus mediates HTLV-1 internalization. Furthermore, DC-SIGN binds ICAM-3 
that  is  expressed  on  T-lymphocytes  and  mediates  transient  adhesion  of  DCs  to  T  cells,  possibly 
allowing transfer of the virus. It was also recently shown that two HTLV-1 viral proteins (p12 and 
p30) are necessary for the productive infection of monocyte-derived DCs as measured by the presence 
of  p19
gag  viral  protein  in  the  culture  supernatant  14  days  after  viral  exposure  [52].  Interestingly, 
macaques exposed to p12 knock out viruses remained seronegative. The exact underlying function of 
p12 in vivo has not been elucidated, but these results suggest that infection of DCs is required to 
establish and maintain HTLV-1 infection in this animal model.  
Monocytes  and macrophages  might  also  represent  a  putative reservoir  in  vivo. Koyanagi  et  al. 
showed that the PVL ranged between 0 and 140 copies per 10
4 monocytes in a group of 22 HTLV-1-
infected individuals [39]. A latent infection of monocytes, which would allow them to escape immune 
recognition,  was  hypothesized  [53].  Viral  reactivation  could  then  be  induced  upon  monocyte-to-
macrophage differentiation. This model is consistent with in vitro experiments showing that HTLV-1-
LTR-driven  luciferase  transcription  was  activated  upon  differentiation  of  a  transiently  transfected 
monocytic cell line into macrophages, in an AP-1-dependent manner [53]. Infection of monocytes and 
monocyte-derived cells could be of particular interest in the context of mother-to-child transmission. 
Indeed, breast milk predominantly contains macrophages, rather than T cells. This could explain how 
prolonged breastfeeding leads to viral transmission. A recent article showed that an in vitro-infected 
breast  milk  macrophage  cell  line  could  transmit  the  virus  to  peripheral  blood  lymphocytes  [54], 
supporting the hypothesis that these cells may be a viral reservoir. However, the presence of HTLV-1 
in breast milk macrophages has not yet been reported in vivo.  
Finally, HTLV-1 infection of activated NK cells was documented in vitro [55], but has not been 
demonstrated in vivo. Infection of iNKT cells was however recently demonstrated in vivo, in ACs and 
HAM/TSP patients [47]. The physiopathological consequences of putative NK infection and of iNKT 
infection will be analyzed in further sections. 
 Viruses 2011, 3                         
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Table 1. Interplay between innate immune cells and HTLV-1. See text for details. ND, not determined. 
 
Infection by 
HTLV-1 
Control of HTLV-1 Replication 
Infection-Induced Alteration 
of Cell Numbers in vivo 
Infection-Induced 
Alteration of Function 
Monocytes / 
Macrophages 
Demonstrated 
in vitro and in vivo 
[39,43,44] 
ND  ND 
Alteration of the in vitro 
differentiation into functional 
dendritic cells (DCs) [56,57] 
Dendritic Cells 
myDCs 
Demonstrated 
in vitro and in vivo 
[45]
1 [46,48] 
- Secretion of IFN- upon in vitro 
HTLV-1 sensing [58]
2 
Decreased  
(ATLL and HAM/TSP patients) 
[46,47] 
ND 
pDCs 
Demonstrated 
in vitro and in vivo 
[46–48] 
- Secretion of IFN- and 
maturation into killer pDCs upon 
in vitro HTLV-1 sensing [59] 
- Inverse correlation between the 
PVL and the ability of ex vivo-
stimulated cells to produce IFN- 
(ACs) [46] 
Decreased  
(ATLL and HAM/TSP patients) 
[46,47] 
Alteration of the ability to 
secrete IFN- upon ex vivo 
stimulation (ACs) [46] 
Natural Killer Cells 
Demonstrated only 
in vitro, on 
activated cells [55] 
Inverse correlation between 
infected cell lines sensitivity to 
NK-mediated cell lysis and 
tumorigenicity in SCID mice [60] 
Decreased  
(ATLL and HAM/TSP patients) 
[47,61] 
High rate of ex vivo 
proliferation (ACs and 
HAM/TSP patients) [62] 
Invariant Natural Killer 
T Cells 
Demonstrated 
in vivo [47] 
Inverse correlation between the 
PVL and iNKT cells frequency 
(ATLL and HAM/TSP patients) 
[47] 
Decreased  
(ATLL and HAM/TSP patients) 
[47,63] 
Low rate of ex vivo 
proliferation and perforin 
production in infected 
individuals [47] 
1 Incomplete cell subtype characterization in [45] due to the absence of any DC-specific antibody available at that time;  
2 Murine bone marrow-derived DCs. Viruses 2011, 3                         
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3. Do Innate Immune Cells Control HTLV-1 Replication? 
3.1. DCs 
Even though a number of studies have tried to evaluate whether exogenous IFN- alone or in 
combination with other molecules (see below), could play an antiviral role during the treatment of 
HAM/TSP  or  ATLL  patients,  IFN-  production  was  not  measured  in  vivo  in  HTLV-1-infected 
individuals  (humans  or  animals).  A  recent  in  vitro  study  suggested  that  normal  human  pDCs  are 
activated  and  able  to  secrete  IFN-  by  a  TLR-7-dependent  mechanism  when  put  in  contact  with 
concentrated purified HTLV-1 virions [59] (Figure 1). Whether or not those pDCs were infected after 
exposure to virus was not evaluated [59], although infection of pDCs following exposure to cell-free 
virus was previously shown by others [48]. Incubation of these pDCs with the virus also led to TRAIL 
relocalization  at  the  membrane,  allowing  induction  of  apoptosis  in  DR5-expressing  T  cells.  It  is 
therefore  possible  that  HTLV-1  activates  pDCs  and  triggers  their  differentiation  into  killer  pDCs. 
Another  study  showed  that  a  chimeric  HTLV-1  (HTLV-1  bearing  a  MLV  envelope)  induces  the 
activation of murine bone marrow-derived DCs, as monitored by the up-regulation of surface markers 
(CD80, CD86 and MHC-II) and the production of IFN-I [58]. These results suggested that infected 
human pDCs or murine DCs have an intact IFN-I induction pathway.  
Hishizawa et al., however, demonstrated that pDCs isolated from a small number of HTLV-1 ACs 
had impaired  IFN-  production, consistent with previous observations reporting  impaired immune 
function in some ACs [64–66]. Is it possible to reconcile these observations? In fact, there is a major 
difference between those studies. In the first ones [58,59], incoming viruses were used to activate the 
TLR-7 pathway and subsequently, IFN-I production. In the ex vivo study [46], pDCs are likely to be 
already infected, probably expressing viral proteins, including Tax, which was shown to blunt IFN 
induction  (see  below).  It  is  therefore  not  surprising  that  those  DCs  do  not  produce  IFN-I  upon 
re-stimulation.  
Finally, Hishizawa et al. also found a negative correlation (Table 1) between the PVL in ACs and 
the ability of pDCs isolated from these individuals to secrete IFN- ex vivo [46]. Although further 
investigation  is  needed  to  demonstrate  the  causative  relationship  between  both  parameters,  these 
results may indicate that efficient  IFN-I production could limit viral replication and hence protect 
against a high PVL. Alternatively, another interpretation of this study is that when PVL increases, the 
number of infected pDCs also increases and therefore their ability to secrete IFN-I is lowered. 
   Viruses 2011, 3                         
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Figure 1. Interplay between HTLV-1 and the type-I interferon (IFN-I) induction pathway. 
A  simplified  schematic  of  the  TLR-induced  IFN-I  induction  pathway  is  shown. 
Recognition of PAMPs by TLR3 induces the recruitment of the adaptor molecule TRIF. 
TRIF activates via TRAF3 the kinases TBK1 and IKK that phosphorylate IFR3 and IRF7 
transcription factors. IRF3/7 heterodimers activate transcription of IFN-I (especially IFN-). 
This  initial  transcription  and  synthesis  wave  is  followed  by  a  second  wave  of  IFN- 
resulting  from  an  amplification  loop  that  involves  IRF7.  TLR7,  8  and  9,  specifically 
expressed  in  pDCs,  activate  IRF7,  which  stimulates  synthesis  of  IFN-  via  MyD88, 
IRAK1/4  and  TRAF6.  In vitro,  sensing  of  HTLV-1  induces  TLR7-dependent  IFN- 
secretion by pDCs [59]. However, pDCs isolated from HTLV-1-infected individuals show 
an altered ability to produce IFN- in response to viral stimulation (e.g., by HSV-1) [46]. 
In  vitro,  HTLV-1  Tax  targets  IRF3  function,  but  the  data  are  conflicting:  while  some 
indicate an inhibitory effect of Tax mediated by SOCS1-induced IRF3 degradation [67], 
others show constitutive activation of IRF3 by Tax [68].  
 
 
3.2. NK Cells  
It  was suggested that an NK response can be  mounted against HTLV-infected cells  (Table 1). 
Indeed, there is a correlation between the level of viral mRNA and protein expression in HTLV-1-Viruses 2011, 3                         
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positive cell lines and their sensitivity to NK-mediated cell lysis [60], suggesting that expression of 
HTLV-1  triggers  alterations  of  the  cell  markers  that  are  recognized  by  NK  cells.  Similarly,  the 
sensitivity  of  HTLV-1-positive  cell  lines  to  NK-mediated  cell  lysis  was  inversely  correlated  with 
tumorigenicity in a SCID model [60], implying that NK cells may prevent tumor induction and/or its 
development in vivo. However, whether NK cells represent an efficient defense mechanism is still 
debated. In addition, results obtained using in vitro-infected cell lines were not confirmed when using 
in vitro-infected primary CD4
+ T cells. A recent study showed that in vitro-infected CD4
+ T cells were 
susceptible to autologous NK cell lysis similar to mock-infected cells, despite having reduced MHC-I 
expression [69]. Since viral proteins such as Tax and p12 also affect the expression of markers at the 
surface of an infected cell (see below), these conflicting results might reflect major differences in viral 
protein  expression  levels  between  in  vitro-infected  cell  lines  and  primary  cells.  Determining  the 
susceptibility of cells from HTLV-1-infected individuals to NK-mediated lysis should allow a better 
understanding of the importance of these cells as a defense mechanism against HTLV-1. 
3.3. iNKT Cells 
An inverse correlation between PVL and the frequency of iNKT cells was demonstrated in ACs and 
HAM/TSP patients [47]. These results suggest that these cells might mount an effective anti-HTLV 
response and that depletion of this compartment might be involved in HTLV-1 physiopathology. In 
line with this hypothesis, stimulation of PBMCs isolated from ACs with -galactosylceramide, the 
prototypical  antigen  used  for  iNKT  stimulation,  induced  ex  vivo  expansion  of  iNKT  cells  as  
well as decreased PVL in the total PBMCs, indicating that expanded iNKT cells have anti-HTLV-1 
activity [47]. 
4. Does HTLV Alter the Innate Response?  
4.1. Alteration of Innate Immune Cell Phenotype, Function and Abundance in the Context of HTLV-1 
Infection 
Several studies were designed to monitor a possible functional alteration of innate immune cells, in 
the context of HTLV-1 infection. In a physiological situation, these cells are fully efficient if they are 
able to arise from precursors in an adequate environment, become activated upon stimulation and 
differentiate into effectors cells.  
4.1.1. Monocytes, Macrophages and DCs 
A series of studies performed in the 90s had shown that HTLV-1-infected macrophages and DCs 
could  favor  T  cell  proliferation  [45,70,71].  This  suggested  that  infection  enhanced  the  antigen-
presentation and T cell-stimulation functions of DCs, potentially participating in the spontaneous T 
cell proliferation that has been observed in patients. However, this model was not supported in recent 
results, which demonstrated that monocytes isolated either from HTLV-1-infected ACs, or individuals 
with ATLL or HAM/TSP, are deficient in their ability to differentiate into functional DCs [56,57]. In a 
physiological context, activated DCs express high levels of adhesion molecules, MHC antigens and 
co-stimulatory molecules, which all cooperate to potentiate the antigen-presenting function of these Viruses 2011, 3                         
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cells, and their ability to induce activation of T lymphocytes. In addition, DCs derived from in vitro 
cultured infected monocytes express abnormal levels of CD1a, CD83, CD86 and HLA-DR, and are 
poorly able to activate autologous T lymphocytes. As mentioned earlier, MDDCs are not identical to 
in vivo or ex vivo purified cells [8]. Hence, the in vivo relevance of these results should be carefully 
investigated. 
pDCs are the main producers of IFN-I. As stated above, isolation of pDCs from HTLV-1-infected 
or  uninfected  individuals  revealed  that  HTLV-1  status  was  associated  with  a  defect  in  IFN- 
production after in vitro stimulation [46]. The impact of HTLV-1 infection on the number of DCs was 
also assessed in vivo [46,47]. ATLL and HAM/TSP patients had a lower absolute number of myDCs 
and pDCs than uninfected individuals, while this was not the case for ACs. The correlation between 
DC  number  and  clinical  status  suggests  that  the  depletion  of  DCs  could  play  a  role  in  HTLV-1 
physiopathology. It should however be emphasized that measurements of cell numbers were performed 
on peripheral blood samples. Whether DCs present in the blood accurately reflect the systemic pool of 
DCs that are present in other tissues is currently unknown. In particular, the observed depletion of DCs 
in the blood could be the consequence of a massive migration of DCs into tissues.  
4.1.2. NK Cells 
Similar  to  monocytes  and  DCs,  altered  function  and  frequency  of  NK  cells  were  reported  in 
HTLV-1-infected individuals. Significantly decreased NK cell activity [72], together with decreased 
NK cell abundance was described  in HAM/TSP patients, [61]. A low frequency of NK cells was 
reported in HAM/TSP as well as in ATLL patients [47]. However, NK cells from ACs and from 
patients  with  HAM/TSP  showed  a  high  proliferation  rate  ex  vivo,  that  was  similar  to  the  high 
proliferation rate of CD8
+ T cells in infected individuals [62]. Since NK proliferation was measured 
without prior cell sorting, it may be due to paracrine interactions among PBMCs, rather than to viral 
expression, which has not been demonstrated in NK cells so far. This ability to proliferate in vitro 
might not be visible in vivo due to competition for limited resources with other cell types such as 
infected CD8
+ T cells that are also known to have a high proliferation rate. Moreover, the absolute 
number of NK cells for each infected individual (rather than their frequency among total PBMCs) was 
not provided in this study. It is therefore possible that the number of NK cells present in the blood 
might not reflect the total number in the whole body [47]. Thus, the effect of HTLV infection on the 
physiology of NK cells still needs to be clarified.  
4.1.3. iNK T cells  
iNKT cells were shown to be less abundant in HAM/TSP and ATLL patients than in uninfected 
individuals [47,63]. iNKT cells from infected individuals also demonstrated a low proliferation rate 
and  reduced  levels  of  perforin  production  in  response  to  ex  vivo  stimulation,  indicating  a  severe 
functional impairment [47]. 
Taken together, these results indicate that HTLV-1 can alter innate immune cell functions, which 
has led some groups to search for a role of individual viral proteins in modulation of the molecular 
pathways involved in innate function. 
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4.2. Alteration of Molecular Pathways by HTLV-1 
4.2.1. Modulation of IFN-I Production  
IRF3  and  IRF7  play  essential  roles  in  the  early  phase  of  IFN-I  gene  activation.  IRF3  is 
constitutively  expressed  and  activated  through  its  carboxy-terminal  phosphorylation  by  IKKε  and 
TBK1. This promotes the transactivation of downstream genes such as IFN-β. In contrast, IRF7 protein 
is synthesized de novo upon IFN stimulation and contributes to amplification of the IFN response, by 
inducing  expression  of  IFN-α  [67].  A  very  recent  study  of  ex  vivo  CD4
+  cells  isolated  from  
30 HTLV-1-infected individuals (ACs, HAM/TSP, ATLL) demonstrated that SOCS1 (Suppressor Of 
Cytokine Signaling 1) is strongly up-regulated in ACs and patients with HAM/TSP but not in those 
with  ATLL.  This  protein  was  previously  shown  to  suppress  IFN  signaling  by  preventing  STAT1 
phosphorylation [73]. Interestingly, SOCS1 expression correlated with HTLV-1 PVL in CD4
+ cells 
obtained from  HAM/TSP  patients. Tax  was  recently shown to promote the expression of SOCS1 
in vitro [74]. In PBMCs transfected with an HTLV-1 molecular clone, IRF3 dimer formation (a marker 
of its activation) does not occur, and SOCS1 expression seems to induce its proteasomal degradation 
(Figure  1).  In  contrast,  silencing  IRF3  expression  in  HTLV-1  transfected  Jurkat  cells  resulted  in 
increased HTLV-1 mRNA expression. Together, these results suggest that HTLV-1-infected cells that 
express viral mRNAs (and in particular tax) are likely to be impaired for early IFN induction signaling.  
These observations are, however, not consistent with a previous report where Suzuki et al. showed 
that HTLV-1 infection and in particular Tax expression leads to constitutive IRF3 phosphorylation and 
activation in HTLV-1-transformed cell lines [68] (Figure 1). It is worth noting that these studies were 
not  performed  using  the  same  experimental  models:  primary  cells  transfected  with  a  viral  DNA 
molecular clone (most likely expressing low levels of virus) [67] vs. laboratory cell lines where 100% 
of the cells are infected and constitutively produce high amounts of infectious virions [68].  
Additional experiments should therefore be performed to determine the effect of HTLV-1 infection 
on  IRF3 levels  or  activity, and  conversely, the effect  of  IRF3 activity on HTLV-1 infection.  For 
example, it would be of interest to transfect primary cells with an HTLV-1 molecular clone, then  
co-cultivate them with an HTLV-1 reporter cell line where IRF3 expression would be suppressed. This 
would reveal whether or not IRF3 plays a role in HTLV-1 expression following virus infection. One 
could also measure levels of IFN secretion in cells that overexpress SOCS1.  
The viral p30 protein was also shown to modulate innate cell activation [75]. Expression of p30 in 
human macrophages (i.e., the THP-1 cell line) alters TLR4 signaling, a critical pathway in the innate 
response to bacterial infection, and inhibits the production of pro-inflammatory cytokines normally 
secreted in response to TLR4 stimulation [75]. This altered TLR4 signaling is due to down-regulation 
of TLR4 expression and is mediated by an interaction-dependent inhibition of the transcriptional factor 
PU.1.  p30-mediated  inhibition  of  pro-inflammatory  signaling  is  accompanied  by  a  stimulation  of 
anti-inflammatory  cytokine  secretion  such  as  IL-10,  suggesting  that  p30  might  interfere  with  the 
balance of pro- and anti-inflammatory responses during bacterial infection. 
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4.2.2. Modulation of IFN-I Signaling  
Following  IFNAR-1/IFNAR-2  engagement  by  IFN-I,  the  Jak1  and  Tyk2  proteins  are 
phosphorylated and induce a signaling cascade involving STAT1 and STAT2. Several reports showed 
that  HTLV-1-infected  cells  still  express  IFNAR  receptors  [25,26].  Therefore,  if  a  defect  in  IFN 
signaling exists,  it must be downstream  from  IFNAR binding.  Indeed, one  report has  shown  that 
HTLV-1  prevents  IFN-I  signaling  in  HeLa  cells  in  vitro  [25]  (Figure  2).  Interestingly,  HTLV-1 
expression  led  to  decreased  Tyk2  and  STAT2  phosphorylation,  two  major  players  in  the  IFN-I 
signaling pathways. This effect was not mediated through env or pol expression, was independent of 
the NF-B pathway, and might be mediated through Gag or Protease expression. Unfortunately, the 
effect of Tax overexpression was not analyzed, so it remains unclear whether or not this protein is 
involved in the process. Downstream of Tyk2 and STAT2 phosphorylation, the active ISGF3 complex 
(Interferon  Stimulated Gene Factor 3),  containing  phosphorylated STAT1,  STAT2,  IRF9,  and the 
CBP/p300 transcription co-activators, triggers the expression of a number of genes. In addition to its 
effect  on SOCS1, Tax overexpression  also  alters  ISGF3 function by preventing interaction  of the 
STAT2  component  of  ISGF3  with  CBP/p300,  therefore  leading  to  modulation  of  the  IFN- 
transduction  cascade  [27]  (Figure  2).  The  level  of  STAT2  phosphorylation  was  however  not 
determined in this work.  
4.2.3. Modulation of Cell Susceptibility to NK-Mediated Cell Lysis  
As mentioned above, whether NK cells can lyse HTLV-1-infected cells is not clear. It has been 
established that the viral auxiliary protein p12, an endoplasmic reticulum-resident protein, can interact 
with the MHC-I heavy chain and inhibit its maturation [76]. This leads to the retro-translocation of 
MHC-I out  of the endoplasmic reticulum and its  degradation by the proteasome, thus  limiting its 
expression at the cell surface [76]. While this allows escape from CTL recognition, it should also allow 
NK cells to recognize infected cells. Interestingly, it was shown that HTLV-1-infected primary CD4
+ T 
cells have a p12-dependent decreased expression of ICAM-1 and -2 adhesion molecules, and of NK 
cell activating receptor NCR and NKG2D ligands, which protects them from NK-mediated lysis [69]. 
Thus, p12 expression might confer resistance to both adaptive and innate NK-dependent cytotoxicity 
mechanisms. 
5. Treating HTLV-1 ATLL or HAM/TSP Patients with IFN-I 
IFN-I has cytostatic and antiviral properties and therefore provides a possible approach for treating 
chronically infected individuals. Though the literature suggests that (i) HTLV-1-infected cells have an 
impaired ability to activate innate immunity and that (ii) a number of HTLV-1 encoded proteins blunt 
IFN-I signaling, a series of clinical trials using IFN-I were performed in Japan [77–83] and in the 
United States [84] to treat HAM/TSP patients with IFN- or -. While some of these studies only 
analyzed clinical parameters  [77], others also evaluated virological markers [82,84]. Doses ranged 
from 0.3 to 3.10
6 (IU) by intra-muscular injection for a period ranging from 4 to 793 days. However, in 
most  cases,  the  treatment  duration  did  not  exceed  a  month.  IFN-  treatment  of  a  group  of  
25 HAM/TSP patients led to a significant although slight decrease of HTLV-1 PVL and to a limited Viruses 2011, 3                         
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improvement of the clinical status [82]. This study also demonstrated that IFN- treatment was more 
efficient in patients with shorter disease duration and a better OMSD (Osame’s motor disability) score. 
Interestingly, it was also reported that the frequency of the CD8
+ effector T cells inversely correlated 
with PVL [82]. Nevertheless, both PVL and clinical symptoms returned to pretreatment values few 
weeks/months after drug administration was stopped. 
Figure 2.  Alteration of the IFN-I signaling pathway by HTLV-1.  Binding of IFN-I on 
IFNAR-1  and  IFNAR-2  IFNAR  receptors  activates  the  Jak1  and  Tyk2  kinases,  which 
phosphorylate STAT1 and STAT2 proteins. Activated STATs form heterodimers that bind 
to  IRF9  to  generate  the  ISGF3  complex.  This  complex  migrates  into  the  nucleus  and 
activates  the  transcription  of  ISGs  by  recruiting  the  co-activator  CBP/p300.  HTLV-1 
hinders Tyk2 and STAT2 phosphorylation. Moreover, HTLV-1 Tax interacts with CBP/p300 
and inhibits its recruitment by the ISGF3 complex. From data published in [25,27]. 
 
 
Oh et al. evaluated the clinical and virological efficacy of escalating doses of IFN- (30 g once a 
week up to 60 g twice a week) during a 28-week period in a small number of HAM/TSP patients  
(n  =  12)  whose  disease  duration  ranged  from  2  to  20  years  [84].  Although  the  clinical  benefits 
(improvement in the Nine-Hole Peg test) were very limited, and even if the PVL was not affected by 
treatment, a reduction of tax mRNA and of HTLV-1 specific CD8
+ cells was observed. Viruses 2011, 3                         
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IFN- combined with AZT is now being used to treat the leukemic, chronic and smoldering forms 
of ATLL [29], although its precise mechanism of action remains to be determined [85]. IFN- was 
also recently used in combination with AZT and arsenic trioxide in a phase II study that was performed 
in 10 newly diagnosed patients with chronic ATLL, and showed some promising effects with 100% 
survival, no relapse and no progression after several months [34,35].  
6. In vitro IFN- or - Treatment of HTLV-1-Infected Cells 
After it was shown that IFN-I displayed some effects in vivo (almost exclusively when combined 
with other drugs), researchers tried to define its mechanism of action in vitro. One study demonstrated 
that treating 293T cells transfected with an HTLV-1 molecular clone (i.e., DNA) with IFN- led to 
decreased virion production measured by the presence of p19
Gag in the cell culture supernatant. This 
decreased virion production was not a result of reduced transcription or translation but rather, was due 
to inhibition of HTLV-1 assembly by preventing the interaction of p19
Gag with lipid rafts [24]. The 
recent discovery of tetherin as a new component of the innate immune response that is inducible by 
IFN [86] and prevents HTLV-1 release [87] might explain these results, and should be investigated. 
Consistent with this work, Kinpara et al. then reported that co-cultivation of 293T human cells or 
NIH3T3  murine  cells  together  with  IL-2-dependent  HTLV-1-infected  cells  derived  from  different 
ATLL patients also resulted in decreased p19
Gag in the cell culture supernatant. However, in this study 
the effect was due to transcriptional repression of HTLV-1 expression, and these effects were mediated 
mostly through IRF7-dependent IFN- secretion by murine epithelial cells [88]. Interestingly IFN- 
did not prevent HTLV-1-infected cells from proliferating and did not induce cell death [26,88]. Since 
lymphoid tissues are enriched in stromal cells in vivo, it is conceivable that those uninfected cells 
would secrete IFN-I after they establish contact with infected CD4
+ cells. This could control HTLV-1 
expression in these infected lymphocytes. Together, these results suggest that, IFN-I can alter HTLV-1 
production in vitro, although the precise mechanism of action remains to be clarified. 
7. Conclusions 
The  different  reports  that  have  been  published  on  the  interplay  between  HTLV-1  infection  or 
HTLV-1 protein expression and innate immune cells in vitro sometimes seem difficult to reconcile 
with observations that were made in vivo. Indeed, a significant number of reports clearly demonstrate 
that HTLV-1-infected cells have a reduced ability to act as members of the innate immunity network 
and that HTLV-1 proteins, in particular Tax, prevent both type I IFN secretion and IFN signaling. 
Nevertheless, combinations of IFN-/AZT or IFN-/AZT/arsenic trioxide represent efficient means to 
obtain complete remission in most ATLL subtypes (except the lymphoma type) and in the murine 
ATLL model. This might be due to the fact that human or murine ATLL cells barely express Tax and, 
therefore still possess an intact IFN signaling pathway and are sensitive to IFN-/AZT. In addition, 
arsenic  trioxide,  by  promoting  the  degradation  of  Tax  could  also  restore  IFN  signaling.  Less 
pronounced IFN- effects in HAM/TSP patients are likely to be due to a higher Tax expression, which 
then impairs IFN signaling. Finally, in ATLL patients exogenous IFN-I might also act on uninfected 
cells and render them less susceptible to infection.  Viruses 2011, 3                         
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In  conclusion,  understanding  the  intimate  interplay  between  HTLV-1  and  the  innate  immune 
response will require additional studies. It will also be crucial that future work aimed at defining these 
interactions be performed with patient samples and primary cells in order to avoid overexpression 
systems that might lead to misinterpretation of the results. 
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